Specifically, for down-regulated genes: LTBR is a receptor for LTbeta in the NF-κB alternative pathway in humans and CD40LG (or CD40L) can be a ligand for NF-κB alternative pathway, both indicating canonical pathway activation in lymphoma rather than alternative pathway activation for NF-κB [41]. This evidence concerns the gene NFKB1 and lymphoma.